Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

24.58
-1.7900-6.79%
Pre-market: 24.00-0.5800-2.36%04:01 EDT
Volume:401.48K
Turnover:10.03M
Market Cap:1.36B
PE:-9.76
High:26.55
Open:25.86
Low:24.39
Close:26.37
52wk High:53.65
52wk Low:20.00
Shares:55.25M
Float Shares:37.25M
Volume Ratio:1.07
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5172
EPS(LYR):-3.0510
ROE:-37.35%
ROA:-21.79%
PB:3.00
PE(LYR):-8.06

Loading ...

Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543

Reuters
·
Yesterday

Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65

Reuters
·
Sep 04

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75

Reuters
·
Sep 01

Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Dow Jones
·
Aug 27

Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement

Reuters
·
Aug 18

Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors

Reuters
·
Aug 18

Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares

Reuters
·
Aug 15

Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board

Reuters
·
Aug 14

Maze Therapeutics Announces Appointments to Its Board of Directors

THOMSON REUTERS
·
Aug 14

CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge

Reuters
·
Aug 14

Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization

TIPRANKS
·
Aug 13

Belite Bio Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

TIPRANKS
·
Aug 12

Humacyte Q2 Net Loss Widens on Inventory, Production Costs

Reuters
·
Aug 12

Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln

Reuters
·
Aug 12

Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target

TIPRANKS
·
Aug 12

Maze Therapeutics Price Target Maintained with a $46.00/Share by BTIG

Dow Jones
·
Aug 12

Press Release: MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

Dow Jones
·
Aug 12

Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate

Benzinga Earnings
·
Aug 12